New collaborations at the German drug maker Evotec are in part behind Wednesday’s report of a rise in full-year revenue, the company said. The group has announced a priority reset, which is expected to result in an annualized Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) improvement of over €40 million ($42.8 million), the company said in a statement. Mario Polywka, chief executive of Evotec, said: “Evotec’s business displayed great resilience in a challenging market environment. Our central focus for 2024 is to protect our strong balance sheet and refocus the company…